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3628 JOURNABSTRACT: Categorical measures of lorazepam sleepiness and dizziness were modeled to
identify differences in pharmacodynamic (PD) parameters between these adverse events
(AEs). Differences in data-derived PD parameters were compared with relative incidence rates
in the drug label (15.7% and 6.9%, respectively). Healthy volunteers (n¼ 20) received single
oral doses of 2 mg lorazepam or placebo in a randomized, double-blind, cross-over fashion. A
seven-point categorical scale measuring the intensity of AEs was serially administered over
24 h. The maximum score (MaxS), and area under the effect curve (AUEC) were determined
by noncompartmental methods and compared using a paired t-test. Individual scores were
modeled using a logistic function implemented in NONMEM. AUEC and MaxS for sleepiness
were significantly higher than dizziness (20.35 vs. 9.76, p< 0.01) and (2.35 vs. 1.45, p< 0.01).
Model slope estimates were similar for sleepiness and dizziness (0.21 logitsmL/ng vs.
0.19 logitsmL/ng), but baseline logits were significantly higher for sleepiness (2.81 vs.
4.34 logits). Data-derived PD parameters were in concordance with label incidence rates.
The higher intensity of sleepiness may be directly related to baseline (no drug present) while the
increase in intensity as a result of drug was relatively similar for both AEs.  2010 Wiley-Liss, Inc.
and the American Pharmacists Association J Pharm Sci 99:3628–3641, 2010Keywords: lorazepam; sleepiness; dizziness; adverse events; ordered categorical; pharma-
codynamicsINTRODUCTION
Ordered categorical scales have been used in a variety
of clinical settings to measure subjective effects and
feelings, which are clinically relevant yet difficult to
measure using objective tests. A good example is pain
where several analgesic trials used various catego-
rical scales.1,2 Such scales have been reported to
display high validity and reproducibility2,3 during
repeated assessments and are usually quick and easy
to administer.1
Pharmacokinetic–pharmacodynamic (PK/PD)
modeling of categorical responses may also provide
insight into the PD of adverse events (AEs). Thence to: Mohamed A. Kamal (Telephone: 650-467-
467-8001; E-mail: mohamed.kamal@roche.com)
aceutical Sciences, Vol. 99, 3628–3641 (2010)
, Inc. and the American Pharmacists Association
AL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 8, AUGUSTfeasibility of using different subjective scales as
biomarkers of AEs was investigated in a small clinical
pharmacology study.4 As part of that study, seven-
point ordered categorical scales measuring different
types of subjective response (e.g., sleepiness, dizzi-
ness, etc.) were administered serially after single-
dose administration to measure intensity of drug
effects over 24 h. Inspection of the effect-time profiles
of the more common drug effects showed differential
profiles for the different CNS agents, the onset and
offset of response as well as the relationship to plasma
concentrations.
The current analysis focuses on the categorical
measures of two AEs of one of the representative CNS
drugs studied,4 namely lorazepam sleepiness and
dizziness, with an aim to identify differences in
relevant pharmacodynamic parameters using a PK/
PD modeling approach. To date, no pharmacody-
namic data, whether being categorical or continuous,2010
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sleepiness and dizziness in the context of population
modeling. Their incidence rates in the drug label offer
a unique benchmark for comparison. Thus, any
differences found in PD measures between sleepiness
and dizziness in the current analysis will be compared
with differences in incidence rates in the drug label.5
From the spectrum of CNS effects measured in the
larger study,4 lorazepam sleepiness and dizziness
were selected as the endpoints of interest because:
(1) these effects showed a relatively high-scale signal
amplitude and highest statistical significance in the
time-averaged change from baseline differences with
placebo, (2) sleepiness is a more common AE of
lorazepam than dizziness according to incidence rates
in the label,5 and (3) their pharmacology is thought to
be conferred by benzodiazepine receptor activity in
distinctly different areas of the CNS.6,7 It must be
noted that modeling categorical data cannot be
performed using conventional nonlinear regression
because it has a polynomial distribution which
violates the assumption of homogeneity of variance.8
Therefore, the probabilities of reporting the effect
categories as a function of time are typically modeled
using logistic regression. The current study employs a
logistic function9,10 to model sleepiness and dizziness
categorical scores and assesses model performance
using previously published pharmacometric metho-
dology.11,12METHODS
Data Collection
Twenty healthy volunteers were randomized in a
double-blind, single-dose, five-way crossover design.4
All subjects gave written informed consent to
participate in the study. The study was conducted
at the Clinical Pharmacology Unit of Pfizer (Ann
Arbor, MI) in accordance with the principles of the
Declaration of Helsinki. The study protocol was
approved and performed in compliance with the
Institutional Review Board/Independent Ethics Com-
mittee (IRB/IEC) and International Committee on
Harmonization (ICH) Good Clinical Practice guide-
lines. Each subject received an oral dose of either
lorazepam 2 mg, as one of four CNS drugs, or placebo.
All study drugs were commonly used marketed
compounds within their respective therapeutic indi-
cations and were selected to produce different AE
profiles which could potentially be measurable after
single-dose administration. Each regimen was sepa-
rated by a 1-week washout period for a total trial
period of five consecutive weeks. Based on the half-life
of each study drug, this washout period was deemed
adequate to ensure lack of any period effect on
baseline PD measures. Blood samples were drawnDOI 10.1002/jpsbefore dosing and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48,
and 72 h after the morning dose.
Prior to each blood collection during the first 24 h,
a 70-item questionnaire was administered. Items
on the questionnaire covered various complaints,
symptoms, or feelings the subject experienced. For
each statement, the subject was to answer how
strongly he or she felt the complaint, symptom, or
feeling on a seven-point ordered categorical scale. The
seven effect categories were: 0¼none, 1¼minimum,
2¼mild, 3¼moderate, 4¼ significant, 5¼ severe,
and 6¼ extreme.
Analytical Assay
Plasma levels of lorazepam were determined using
liquid chromatography tandem mass spectrometry
(LC/MS/MS) at PPD Development (Richmond, VA).
Briefly, 0.1 mL of human plasma containing sodium
heparin was extracted by a liquid–liquid extraction
using methyl-t-butyl ether. The organic extract was
dried and reconstituted in 0.2 mL of formic acid/
methanol/5 mM ammonium formate (0.1:50:50, v/v/v),
and an aliquot was injected into the LC/MS/MS
system. The compounds were separated by reverse
phase on a C18 column (2.0 mm 50 mm, 5mm) by
gradient elution using a binary mobile phase
consisting of formic acid/methanol/water (0.1:10:90,
v/v/v) and 0.1% formic acid in methanol (v/v). The
analytes were ionized in the mass spectrometer in a
Turbo IonSpray source with positive ion atmospheric
pressure electrospray ionization and detected with
multiple-reaction monitoring modes. The nominal ion
transitions monitored were m/z¼ 321> 275 for
lorazepam and m/z 327> 281 for the internal
standard (lorazepam-d4). These transition ions were
selected based on predominant fragmentation path-
ways of lorazepam and internal standard and their
intensity, as observed in their product ion mass
spectra. The lorazepam standard curve was linear
over the range of 0.5 ng/mL (the lower limit of
quantitation) to 50 ng/mL when 0.1 mL plasma was
used for the analysis (r2> 0.998). The intra- and inter-
assay variations were less than 15% for the spiked
standard curve and quality control samples. The
variations for the quality control samples during the
long-term study were <12%.
Data Analyses
Pharmacokinetics
A noncompartmental analysis13 was performed using
WinNonLin version 5.2 (Pharsight, Inc., Mountain
View, CA) on lorazepam plasma concentration–time
profiles to determine maximal concentration (Cmax),
time to maximal concentration (Tmax), area under the
curve from time zero to infinity (AUC0–1) and the
terminal half-life (t1/2). Compartmental populationJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 8, AUGUST 2010
3630 KAMAL ET AL.analyses were conducted in NONMEM V14 using the
first-order conditional estimation method with inter-
action. The general model building strategy is based
on modification of different approaches discussed by
Beal and Sheiner,14 Mandema et al.,15 and Ette and
Ludden.16 During model building, the goodness-of-fit
of different models to the data was evaluated using
the following criteria: change in the minimum
objective function (MOF), visual inspection of con-
cordance and residual plots, precision of the para-
meter estimates, and decreases in both inter-
individual and residual variability. A decrease in
the MOF of at least 3.8 upon addition of a parameter
was considered statistically significant. This corre-
sponds to a nominal p-value of <0.05 and one degree
of freedom in the chi-square distribution of the
difference of MOF between hierarchical models.
The initial PK model was a one-compartment model
defined in terms of the following structural para-
meters: oral clearance (CL/F), volume of distribution
(V1/F), and first-order rate constant for absorption
(ka). Other models tested include a term for lag time in
absorption (tlag) and/or 2 compartments. Inter-
subject variability on mean PK parameters was
modeled using an exponential error term and was
estimated sequentially on structural parameters such
as oral clearance (CL/F), volume of distribution in the
central and peripheral compartments (V1/F, V2/F),
and on the first-order absorption rate constant (ka).
Various models of residual variability were tested
including additive, proportional and combined addi-
tive/proportional error models. During model build-
ing, the off-diagonal elements of the variance–
covariance matrix were fixed to 0, that is, it was
assumed that there was no correlation between PK
parameters. In the final step, the correlation between
all parameters was estimated in NONMEM.
Parameter estimates of CL/F and t1/2 were com-
pared with the noncompartmental results to ensure
that model was adequate. Confidence intervals
around parameter estimates were generated using
nonparametric bootstrap procedure (n¼ 1000 runs)
as described by Ette et al.11
Pharmacodynamics
To produce a typical value versus time curve for
sleepiness and dizziness categorical scores, the
expected value at each time-point was calculated.
The expected value or average score of the categorical
measure of sleepiness and dizziness at time t can be




xt  PðxÞ (1)
where X is the discrete random variable denoting the
categorical measure of sleepiness or dizziness, xt isJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 8, AUGUST 2010the categorical sleepiness or dizziness score at time t
with a set of possible categorical values m ranging
from 0 to 6, and P(x) is the probability (obtained as a
frequency) of reporting a categorical score x at time t.
To examine whether or not there were differences in
sleepiness and dizziness intensities, a noncompart-
mental analysis of the time course of average
sleepiness and dizziness scores was conducted. Effect
intensity endpoints determined were maximum score
(MaxS) and area under the effect curve (AUEC) over
the entire dosing interval (24 h). A paired t-test was
used to determine whether differences in MaxS and
AUEC between sleepiness and dizziness were statis-
tically signficant.
Population modeling of the time course of sleepi-
ness and dizziness scores was implemented in
NONMEM14 using a logistic function9,10 with the
second-order Laplacian method of estimation14 As the
intensity of pharmacodynamic effect was self-rated on
the seven-point categorical scale (0–6), the logistic
function was used to model the probability (P) of
observing scores pm (m¼ 0–6) as a function of
baseline effect, drug concentrations, and placebo
effect. The logistic function used was:
gPfYt  mhÞg ¼
Xm
i¼1
bm þ drug þ placebo þ h (2)
where g½PfYt  mhÞg is the function describing the
probability of being greater than or equal to a
particular effect category, m;
Pm
i¼1 bm is the sum of
baseline parameters (b1, b2, b3, . . .bm) describing the
baseline probability of experiencing a particular
effect category; ‘drug’ and ‘placebo’ are model
components describing drug and placebo effects;
and h is a subject-specific random effect parameter
quantifying inter-individual variability in response
assumed to be normally distributed with a mean of 0
and variance v.2 The logit transform function was
used to convert the function g½PfYt  mhÞg, which is
in logits, into a probability.
PðYt  mÞ ¼
eðgÞ
1 þ eðgÞ (3)
Initial inspection of sleepiness data showed the
highest reported effect category as 5 (severe). As such,
the probabilities modeled over time were (p 1, p 2,
p 3, p 4, p 5). By definition, p 0¼ 1, and this is
not modeled. For the dizziness data, the highest
reported category was three, and the probabilities
modeled over time were (p 1, p 2, p 3). Model
building was conducted by adding the model compo-
nents in Eq. (2) sequentially and observing the
change in the MOF.
Modeling was initialized on all data (placebo,
baseline, and drug) with incorporation of the baselineDOI 10.1002/jps
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placebo model.
First, baseline probabilities for each effect category
were modeled as constants as described by Sheiner.9
From Eq. (2), b1 is the Y-intercept (in logits)
describing the baseline for reporting an effect
category of at least minimum intensity (one or more),
b2 is the intercept added to b1 to determine the
baseline logit contribution for reporting an effect
category of at least mild (two or more), and so forth.
The drug component was added by beginning with a
simple linear slope function as described below:
E ¼ S  C (4)
where E is the drug effect, S is the slope describing the
relationship between drug effect in the logistic
domain and drug concentrations C. Originally C
was tested as concentration in the central compart-
ment determined by post hoc individual PK para-
meter estimates. Addition of an effect compartment,17
where C in Equation (4) now represents concentration
in the effect compartment, was tested to account for
any delay in effect with respect to peak plasma
concentrations. This required addition of an extra
parameter keo, the first-order rate constant describing
lag in effect in the biophase17 compared with central
compartment concentrations. A Hill function withoutFigure 1. Representative individual profile
(right) to placebo categorical response.
DOI 10.1002/jpsand with a sigmoidicity constant were also tested.
Change in the MOF and inspection of the correlation
matrix of estimates to ensure model stability was
used to select final models.
For the placebo component of Equation (2), several
models were tested including a constant modeled as
a theta14 parameter in logits and a Bateman-like
function. Incorporation of the placebo component in
this manner resulted in the covariance step being
aborted. However, inspection of the individual
placebo profiles revealed some subjects as nonrespon-
ders and others as mild to moderate responders as
shown in Figure 1. As such a mixture model18 on
placebo response was tested. A mixture model
assumes the population is composed of two or more
subpopulations, each having a distinct population
mean and random effects. Therefore, if the subject
belonged to subpopulation 1 of nonresponders, the
placebo response was set to zero. If the subject
belonged to subpopulation 2, the placebo response
was modeled using a Bateman-like function, with a
theta parameter in logits describing the amplitude of
placebo effect, and first-order rate constants describ-
ing the onset and offset of placebo effect.
Assessment of PK/PD Model Performance
Nonparametric bootstrapping11 and simulation based
on bootstrap estimates were performed using SPLUS
VI software (Insightful Corp., Seattle, WA). Ones of nonresponder (left) and responder
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 8, AUGUST 2010








Age, years 43 (11)
Weight, kg 72 (12)
Creatinine clearance, mL/min 103 (22)
3632 KAMAL ET AL.thousand bootstrap runs were conducted to deter-
mine confidence intervals of parameter estimates.
This analysis was repeated using successful bootstrap
runs only. Simulations were then performed using
500 sets of bootstrap estimates to generate five
hundred sets of data as described by Ette et al.11
Using this simulated data, cumulative probability
plots of reporting at least an effect intensity m (pm)
as a function of time were constructed to show the
performance of the model across effect categories.
Ninety percent prediction intervals of the time course
of categorical scores were also constructed to visually
depict the degree of uncertainty in the models because
of random effects and parameter estimate uncer-
tainty. In addition, posterior distributions of relevant
PD endpoints were constructed and overlaid on the
observed mean values as described by Yano et al.12
The PD endpoints selected were those determined in
the PD noncompartmental analysis (i.e., MaxS and
AUEC), as well as the proportion of subjects reporting
an AE of at least mild and moderate intensity.
The current logistic model assumes independence
of two consecutive categorical observations measured
as a function of time. To test that this assumption is
reasonable, the posterior distribution of the number
of different transitions19,20 from the logistic model
were generated for both lorazepam sleepiness and
dizziness and overlaid on the observed mean value.
Comparison of PD Parameters and Label Incidence
The relative ratio of label incidence of lorazepam
sleepiness and dizziness was compared with the
relative ratio of various data-derived PD parameters
including MaxS, AUEC, and the maximum prob-
ability of reporting at least a particular effect
category m (p 1, p 2, p 3). The relative ratio of
model-derived PD parameters such as slope was also
compared with the ratio of label incidence of
sleepiness and dizziness.Figure 2. Observed individual, observed meanSD, and
predicted mean plasma concentrations versus time. Error
bars represent 1 standard deviation above and below the
observed mean data.RESULTS
Pharmacokinetics
Table 1 shows the demographic information of the
20 study subjects. The time course of observed
meanSD, mean predicted, and individual plasma
concentrations after single oral dose administration
of lorazepam 2 mg are shown in Figure 2. A
noncompartmental analysis yielded mean (CV%)
estimates for Cmax of 26.8 ng/mL (22.9), Tmax of
1.7 h (40.8), t1/2 of 16.8 h (21.3) and a total systemic
exposure or AUC0–1 of 551 ng h/mL (31.0). Significant
decreases in the MOF, residual and inter-individual
variability, and inspection of concordance and resi-
dual plots indicated that a two-compartment modelJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 8, AUGUST 2010with first-order absorption adequately described the
time course of plasma concentrations of 2 mg oral
lorazepam.
Table 2 shows the final pharmacokinetic population
parameter estimates. The population mean para-
meter estimates were in good agreement with
parameters derived using noncompartmental analy-
sis for both CL/F (3.63 L/h vs. 4.02 L/h) and the
derived half-life (16.7 h vs. 16.8 h). Epsilon shrink-
age21 was 45%. Results of the nonparametric boot-
strap analysis are included in Table 2. The model was
robust with 87% of the runs minimizing successfully.
The parameter estimates and confidence intervals
obtained from the bootstrap procedure, which
included all runs (even those which failed) were
generally comparable with the estimates derived
from NONMEM. Similar bootstrap estimates and
confidence intervals were obtained using only suc-
cessful runs.
Pharmacodynamics
Noncompartmental analyses conducted on the effect-
time profiles of sleepiness and dizziness scoresDOI 10.1002/jps
Table 2. Pharmacokinetic Parameters in Healthy Volunteers After a 2 mg Oral Dose of Lorazepam (n¼ 20)
Parameter NONMEM Estimate NONMEM 95% CI Bootstrap Estimate Bootstrap 95% CI
CL/F 4.02 3.58–4.46 4.0 3.61–4.49
V1/F 53.6 48.1–59.1 53.3 44.0–59.0
V2/F 37.6 33.3–41.9 37.9 33.4–44.4
Ka 1.04 0.82–1.26 1.03 0.81–1.28
Q 10.9 9.0–12.8 11 9.06–14.23
V-CL/F 25.40% 12.1–38.7 24.44% 16.6–31.18
V-V1/F 9.24% 2.08–16.4 9.07% 2.35–17.0
V-V2/F 13.10% 3.98–19.1 12.00% 4.3–18.38
V-Ka 35.90% 16.4–55.5 34.21% 18.6–44.4
Residual proportional error 8.34% 5.54–11.1 8.06% 5.76–10.7
CL, systemic clearance; F, bioavailability; V1, central compartment volume; V2, peripheral compartment volume; Ka, first-order rate of absorption; Q, inter-
compartmental clearance; V, random effects parameter estimating inter-subject variability.
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the maximum score (MaxS) and area under the effect
curve (AUEC) endpoints. The MaxS of lorazepam
sleepiness (SE) was significantly higher than
dizziness (2.35 0.26 vs. 1.45 0.22, p< 0.01), as
was the AUEC (20.35 3.58 vs. 9.76 2.45, p< 0.01).
The time to reach MaxS for lorazepam sleepiness
scores was delayed (3.98 h, Fig. 3) compared with time
of maximal lorazepam concentrations (1.71 h, Fig. 2).
This observation justified addition of the effect
compartment17 to describe drug effect in the
lorazepam sleepiness model. In contrast, the
dizziness effect peaked (2.55 h, Fig. 3) at a time
similar to that observed for peak plasma drug
concentrations.
Population PD model building was initialized by
addition of baseline logit intercepts for each effect
category. As indicated in Equation (2), these are
added sequentially from i¼ 1 to m to quantify the
probability of experiencing a score category m or
more in the absence of drug or placebo. Table 3 shows
the final PD model estimates. As shown, b1 (which
represents the probability in logits of reporting
a score of 1 or more at baseline) was significantly
higher for sleepiness (2.81) than dizziness (4.34)
as indicated by the 95% confidence intervals. b4 and
b5 were included in the sleepiness model as they
resulted in significant decreases in the MOF. Addi-
tion of the drug component of the model as a slope as
described in Eq. (4) resulted in a decrease in point
reduction in the MOF of 216 and 174 points for
sleepiness and dizziness models, respectively, indi-
cating a significant drug effect. As shown in Table 3,
slope estimates of sleepiness (0.21 logits/mL ng) and
dizziness (0.19) were not significantly different on
inspection of the 95% confidence intervals. Addition
of an effect compartment was significant for sleepi-
ness but not dizziness, and the final estimate of keo,
the first-order rate constant describing lag in effect inDOI 10.1002/jpsthe biophase compared with central compartment
concentrations, was 2.44 h1.
Placebo effect was modeled as a mixture of
nonresponders and responders in the final model,
where the responder component was described using
a Bateman-like function as shown in Figure 1.
Modeling the placebo effect as a mixture, remedied
the initial problem encountered with abortion of the
covariance step and resulted in stabilization of the
final model as indicated by the correlation matrix of
estimates being devoid of high correlations (>0.8)
among parameters. PLAC describes the amplitude of
response and, as indicated in Table 3, was similar for
sleepiness (3.6 logits) and dizziness (4.3 logits) as was
k1, the first-order rate constant describing onset of
placebo effect. When k2, the first-order rate constant
describing offset of placebo effect, was modeled for
sleepiness placebo, it resulted in over-parameteriza-
tion as determined by inspection of the correlation
matrix of estimates. However, given that the indivi-
dual responder profiles showed a Bateman pattern of
effect and not exponential decay, k2 was modeled as a
fraction of k1 and the constant used to determine this
fraction was determined using a sensitivity analysis.
The majority of subjects were nonresponders to
placebo effect as indicated by P(1), the subpopulation
proportion that was nonresponder to placebo, and
this estimate was similar between sleepiness (63%)
and dizziness (71%). The inter-individual random
effects parameter V1 was significantly higher for
sleepiness effect (3.31 logits) compared with dizziness
(0.32 logits).
As shown in Table 3, mean population parameter
estimates obtained from the bootstrap procedure
were generally comparable with the estimates from
the final model. The NONMEM confidence intervals
were also generally comparable with the bootstrap
intervals for most parameters, with the exception of
b5, keo, PLAC, and P(1) of the sleepiness model; andJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 8, AUGUST 2010
Figure 3. Ninety percent prediction intervals of sleepi-
ness and dizziness scores in healthy volunteers as a func-
tion of time (n¼ 20). Panel one shows lorazepam and
placebo sleepiness, panel two lorazepam and placebo dizzi-
ness, and panel three lorazepam sleepiness and dizziness.
Symbols indicate observed data, middle line indicates mean
simulated data, and lower and upper lines indicate lower
and upper prediction interval bounds.
3634 KAMAL ET AL.PLAC, k1, and P(1), of the dizziness model, reflecting
their asymmetric distribution. The success rate of
bootstrap runs was 80% for the lorazepam sleepiness
model and 83% for the dizziness model.
Figure 3 shows the observed (points) and overlaid
mean simulated scores (lines) and 90% shadedJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 8, AUGUST 2010prediction intervals (PIs) obtained from 500 sets of
bootstrap parameter estimates. The mean simula-
tions adequately describe the time course of sleepi-
ness and dizziness scores with the prediction
intervals (shaded region) capturing the data and
mean simulations. The one exception, however, is a
data point of placebo sleepiness (at 6 h), which is
not captured by the model and lies slightly outside of
the shaded interval. The shaded PI for lorazepam
sleepiness is wider than that of lorazepam
dizziness indicating the greater model uncertainty
of sleepiness.
Figure 4 shows the observed and simulated
cumulative probabilities of reporting a sleepiness
and dizziness effect greater than or equal to a
particular effect category over time (pm). The
simulations describe the data adequately. As
shown, the cumulative probabilities decrease with
increasing effect category (m). Moreover, peak pro-
babilities of reporting at least an effect category m at
time of maximal effect are higher for lorazepam
sleepiness (1¼p 1, 0.45¼p 2, 0.25¼p 3, 0.1¼
p 4, 0.05¼p 5) then for lorazepam dizziness
(0.7¼ p 1, 0.3¼p 2, 0. 15¼p 3) as shown in
Figure 4.
Figure 5 shows histograms of the simulated
distribution of MaxS, AUEC, and the number of
subjects reporting an AE of at least mild and
moderate severity obtained from 500 sets of bootstrap
parameter estimates, overlaid on the observed mean
of these PD endpoints (represented by the vertical
black bar). The panels indicate that that proposed
models simulate posterior distributions of these
parameters, which are centered close to the observed
means.
Figure 6a and b shows the posterior distributions of
the number of different categorical transitions for
lorazepam sleepiness and dizziness, respectively,
overlaid on the observed mean. The panels indicate
that the observed population mean lies within the
posterior distributions of the transitions counts for all
simulated transitions. The posterior distributions
capture the observed mean adequately overall with
the exception of few transitions which lie at the tail of
the posterior distribution (transition 1–1 in
Fig. 6a and the transitions 1–0, 2–2, 3–1, and 3–0
in Fig. 6b).
Finally, Table 4 relates the various data-derived
PD parameters, and the model-derived PD para-
meter, slope, to the incidence rates of the AEs in the
more general population, as reported in the drug
label.5 The ratio of the sleepiness/dizziness endpoints
was calculated across these parameters. As shown by
the relative ratios, Max (p 2), Max (p 3), and
AUEC, show the greatest concordance to label in-
cidence, followed by MaxS and Max (p 1). However,
the ratio of sleepiness to dizziness slope parametersDOI 10.1002/jps
Table 3. Pharmacodynamic Parameters in Healthy Volunteers After a 2 mg Oral Dose of Lorazepam or Placebo (n¼ 20)
Model Parameter


















b1 (logits) 2.81 4.0 to 1.62 2.83 4.5 to 1.71 4.34 5.18 to 3.5 4.51 6.40 to 3.70
b2 (logits) 2.57 3.27 to 1.87 2.58 3.37 to 1.94 3.17 4.51 to 1.83 3.34 5.49 to 2.26
b3 (logits) 1.79 2.37 to 1.21 1.84 2.5 to 1.29 1.08 1.68 to 0.48 1.08 2.43 to 0.57
b4 (logits) 2.81 4.02 to 1.59 2.86 4.43 to 1.86 NA NA NA NA
b5 (logits) 1.55 3.44 to 0.34 1.6 64.47 to 6.1E-10 NA NA NA NA
Drug effect
Slope (logitsmL/ng) 0.21 0.17 to 0.25 0.21 0.17 to 0.27 0.19 0.15 to 0.23 0.19 0.15 to 0.25
keo (h
1) 2.44 0.40 to 4.48 2.59 1.28 to 16.1 NA NA NA NA
Placebo effect
PLAC (logits) 3.6 1.74 to 5.46 4.00 1.78 to 8.17 4.30 1.65 to 6.95 5.53 3.09 to 13.01
k1 (h
1) 0.188 0.02 to 0.36 0.175 0.07 to 0.43 0.11 0.07 to 0.29 0.16 0.03 to 1.19
k2 (h
1) NA NA NA NA 2.13 0.17 to 4.09 1.93 0.37 to 3.68
P(1) 62.80% 39.60 to 96.00 64.60% 14.6 to 94.9 71.00% 43.00 to 99.00 64.80% 16.36 to 89.39
Random effects
V1 3.31 0.33 to 6.29 3.12 0.60 to 7.00 0.32 0.62 to 1.25 0.34 0.01 to 2.91
b1–b5, intercept logistic parameters describing the baseline; PLAC, amplitude of placebo effect; k1 and k2, first order rates of onset and offset of placebo
response; P(1), percentage of nonresponders to placebo; SLOPE, relationship between drug effect and concentrations; keo, first-order rate constant describing lag
in the effect compartment compared with lorazepam concentrations in the central compartment; V1, random effects parameter describing inter-subject
variability.
Figure 4. Cumulative probability plots of reporting sleepiness and dizziness. p 1–5
is the cumulative probability of reporting an effect of at least minimum, mild, moderate,
significant, and severe intensity on the categorical scale. Symbols indicate observed
mean data and lines indicate mean simulations.
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Figure 5. Posterior distributions of MaxS, AUEC, and the proportion reporting an AE
of at least mild and moderate intensity for lorazepam sleepiness and dizziness in healthy
volunteers after a 2 mg oral dose of lorazepam (n¼ 20). The vertical line in each plot
indicates the mean observed value. MaxS is the maximum reported categorical score,
AUEC is the area under the effect curve from 0 to 24 h.
3636 KAMAL ET AL.was very close to 1 indicating that drug effect may not
explain the differences between sleepiness and
dizziness across these PD parameters.
DISCUSSION
The current PK/PD analysis of a seven-point ordered
categorical measure aims to differentiate the phar-
macodynamics of two of the most common AEs of
lorazepam, sleepiness and dizziness. The 2 mg dose
of drug selected in this study is within the range of
recommended daily doses of lorazepam for main-
tenance treatment of generalized anxiety disorder.
Studies modeling the intensity of drug AEs over
time are relatively uncommon,19,20 and no studies
have formally applied population PK/PD analyses in
differentiation of AEs.
PK estimates obtained from the noncompartmental
and compartmental analysis of the concentration–JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 8, AUGUST 2010time profiles are consistent with previous reports22
and showed that lorazepam is rapidly absorbed
(ka¼ 1.04 h1), has peak plasma concentrations
occurring at about 2 h postdose and that it has
relatively moderate steady state volume of distribu-
tion (90 L), low systemic clearance (4 L/h), and
moderate terminal half-life (16.7 h).
The noncompartmental analysis of the effect-time
profiles of sleepiness and dizziness scores indicated
that the MaxS of sleepiness was significantly higher
than dizziness (2.35 vs. 1.45, p< 0.01) as was the
AUEC (20.35 vs. 9.76, p< 0.01). As shown in Table 4,
the ratios of sleepiness/dizziness of these PD para-
meters are in concordance to the ratio of label
incidence, with AUEC showing stronger concordance.
While sleepiness and dizziness are the most com-
monly reported AEs of lorazepam according to the
drug label,5 these effects show minimal to moderate
amplitude on the categorical scale as shown inDOI 10.1002/jps
PHARMACODYNAMIC DIFFERENTIATION OF LORAZEPAM SLEEPINESS AND DIZZINESS 3637Figure 3. This observation may underscore the
sensitivity of the seven-point categorical scale in
discerning small differences between relatively mild
to moderate AEs over time.
Differences in reporting various categories of effect
intensity between these AEs are seen in the
cumulative effect probability plots in Figure 4.
Maximum probabilities of reporting at least a
minimal effect, Max (p 1), are higher for lorazepam
sleepiness (p¼ 1) than dizziness (p¼ 0.7). Likewise,
maximum probabilities of reporting at least mild
and moderate intensity, Max (p 2) and Max (p 3),
are higher for lorazepam induced sleepiness
(0.45¼p 2, 0.25¼p 3) than for dizziness
(0.3¼p 2, 0.15¼p 3). As these represent the
cumulative probabilities (which is a frequency) ofFigure 6. (a) Posterior distributions of the n
for lorazepam sleepiness. Transition permuat
categories are shown (categories 0, 1, 2, and 3).
mean number of observed transitions. (b) P
different categorical transitions for lorazepa
all four reported categories are shown (categ
each plot indicates the mean number of obser
DOI 10.1002/jpsreporting an effect of given intensity in a conceptual
population, their relationship to label incidence is
more direct than MaxS and AUEC which reflect effect
intensity rather than effect frequency. As shown in
Table 4, the sleepiness/dizziness ratio across these PD
parameters are also in concordance to the ratio of
label incidence with Max (p 2) and Max (p 3)
showing the highest concordance followed by Max
(p 1). The stronger concordance of Max (p 2) and
Max (p 3) to label incidence seems to suggest that
the frequency of reporting categorical effects of higher
intensity may be better related to incidence in the
more general population.
The lack of significant difference between the model
estimate of slope for sleepiness (0.21) and dizziness
(0.19) at the 95% confidence level suggests that theumber of different categorical transitions
ions of the first four of the reported six
The vertical line in each plot indicates the
osterior distributions of the number of
m dizziness. Transition permuations of
ories 0, 1, 2, and 3). The vertical line in
ved transitions.
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Figure 6. (Continued )
3638 KAMAL ET AL.drug does not contribute to the observed differences in
intensity of these AEs. b1, the baseline intercept
parameter of effect category 1 (likelihood of having a
response of at least minimum intensity), is the only
parameter that is significantly different between
these AEs at the 95% confidence level. The difference
between this estimate for sleepiness and dizziness is
1.5 logits. As shown in Figure 7, which shows the
relationship between the probability and logistic
domains, the majority of the probability domain
(0.1 y 0.9) occurs in the logit range 33, and
0 logits corresponds to the inflection point at y¼ 0.5.
In this range, 1.5 logits corresponds to a probability of
0.82. As 0 logits corresponds to p¼ 0.5, the differenceTable 4. Relationship of Data-Derived and Model-Derived PD
Dizziness in Healthy Volunteers After Administration of a 2 mg
Endpoint/Parameter Label Incidence AUEC Max
Sleepiness 15.7 20.35 2.34
Dizziness 6.9 9.76 1.45
Ratio (sleepiness/dizziness) 2.3 2.1 1.6
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 8, AUGUST 20100.32¼p¼ 0.82–0.5 corresponds to the greater like-
lihood of reporting sleepiness than dizziness as a
result of the baseline difference. From Figure 4, the
difference in observed cumulative effect (p 1) at
Tmax between sleepiness and dizziness is 1–0.7¼ 0.3
equivalent to the value determined above. As (p 1)
is the cumulative effect across all effect categories,
differences in this endpoint between sleepiness and
dizziness at Tmax closely resemble differences in Max
Score.
It is unclear from a physiological standpoint why
the difference in baseline effect exists between
sleepiness and dizziness, but one possible explanation
may be the time of day in which the data wereParameters to the Label Incidence of Sleepiness and
Oral Dose of Lorazepam
S Max (p 1) Max (p 2) Max (p3) Slope
1 0.57 0.35 0.21
0.7 0.25 0.15 0.19
1.5 2.3 2.3 1.1
DOI 10.1002/jps
Figure 7. Relationship between the probability and
logistic domains.
PHARMACODYNAMIC DIFFERENTIATION OF LORAZEPAM SLEEPINESS AND DIZZINESS 3639collected. Given that the scale was first applied in the
morning, some subjects may have experienced a
residual sleepiness in the morning that was reported
at baseline. Another explanation may be that subjects
may have a greater tendency to report a sleepiness
effect than dizziness even in the absence of any drug.
However, no placebo response rates of these effects
are reported in the lorazepam label to confirm this.
Placebo data in the current study, as shown in
Figure 3, show a slightly greater sleepiness response
at earlier time-points (at 0.5 h postdose administra-Figure 8. Upper panel: Sleepiness and dizz
categorical scale versus lorazepam concentrat
ness scores recorded on the Visual Analog Scal
DOI 10.1002/jpstion), suggesting that differences in reporting sleepi-
ness and dizziness in the absence of drug may be
related to time of day.
The PK/PD temporal patterns of sleepiness and
dizziness are shown in Figure 8, depicting the
counterclockwise hysteresis for lorazepam sleepiness
and the closed hysteresis loop for dizziness. The same
PK–PD temporal relationships of these AEs were
recorded on the Visual Analog Scale2,3 administered
in the same study4 as shown in Figure 8 further
corroborating this finding. Other studies have shown
the counterclockwise hysteresis pattern with amne-
sic,23 psychomotor,24,25 and cognitive24,25 effects after
administration of 2 mg oral lorazepam in healthy
adults. These studies estimated greater delays with
slightly lower keo values (keo¼ 1.3–1.7 h1) compared
with the current study (2.4 h1). However, although
correlated to the sedative effect of lorazepam,26 these
amnesic and psychomotor effects are different from
sleepiness. On the other hand, in the current study,
dizziness showed no such significant delay and the
time to MaxS was close to the Tmax of lorazepam
concentrations. While this temporal difference
between AEs is unclear, one pharmacologic explana-
tion may be distributional, that is, lorazepam-induced
sleepiness may require traversing of the blood–brain
barrier whereas dizziness may not. In fact, if indeed
the subjects were reporting vertigo as dizziness,27 this
would require binding to the GABA receptors in theiness scores recorded on the seven-point
ions. Lower panel: Sleepiness and dizzi-
e (VAS) versus lorazepam concentrations.
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3640 KAMAL ET AL.vestibular system of the inner ear which does not
require traversing the blood–brain barrier. However,
the distributional delay is less likely given the high
log P of lorazepam. Moreover, GABA receptor inhibi-
tion of the vestibular axis by lorazepam would
actually be therapeutic to vertigo,28 suggesting that
the biophase of lorazepam dizziness is most likely the
brain itself and not the inner ear. Another explana-
tion is that these AEs may originate from distinct
anatomical locations in the brain. It is known that
lorazepam induced sleepiness is the result of binding
to and inhibition of benzodiazepine receptors of
GABA complexes in the thalamus and sensory cortex
of the brain.6,7 The receptor binding causes down-
stream inhibition of glucose metabolism,6,7 which
might account for the delayed sensation of sleepiness
recorded by the scale. On the other hand, lorazepam-
induced dizziness is conferred by benzodiazepine
action in receptors of the cerebellum (responsible for
maintenance of balance) and these receptors may
have a different subunit composition,29 altering rates
of downstream signaling. If such a pharmacologic
scenario is indeed valid, this delay may be described
using a transduction model.30
The performance of the final population models was
assessed by a number of diagnostics including the
mean simulations in Figure 3, which adequately
capture the time course of drug and placebo scores,
and the simulations in Figure 4, which capture the
observed cumulative probabilities. As a further check
to ensure the models simulate realistic data, posterior
predictive checks (PPCs)12 in Figure 5 were per-
formed and show that the simulated distributions of
MaxS and AUEC were centered close to the observed
mean. These PD parameters were selected based on
them being clinically relevant, data-derived para-
meters, which could be determined using the profile of
an individual subject. These parameters condense the
PD profiles to a single metric (either AUEC or MaxS)
that capture evaluation of peak response and extent
of response similar to a PK analysis. Use of analogous
metrics (AUC and Cmax) for the PPC is recommended
for PK models as discussed by Yano et al.12 Two other
PPC metrics were analyzed: proportion of subjects
reporting a categorical effect of at least mild and
moderate intensity. As shown in Figure 5, the
simulated distributions of these metrics were cen-
tered close to the observed mean as well. The 90% PIs
in Figure 3 show the model uncertainty conferred by
both random effects and uncertainty in estimating
the parameter estimates. Typically, the 90% as
opposed to 95% PI is assessed, because some
confidence to detect a type I error is compromised
to compensate for the increased uncertainty incurred
by random effects. As shown in Figure 3, the PI of
lorazepam sleepiness is wider then dizziness indicat-
ing greater model uncertainty. This may be the resultJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 8, AUGUST 2010of the greater random effects as shown in Table 3 (V is
higher for sleepiness). As overlaying PIs of these
effects shows separation beyond 2 h, one can make the
conclusion that, given uncertainty in the model
estimates and random effects, the models can detect
a difference between the time course (at Tmax and
beyond) of these effects at the 90% confidence level.
The current logistic or proportional odds model
assumes independence of neighboring consecutive
categorical observations as a function of time. The
Markov or transition model19,20 which determines the
conditional probability of reporting an observation at
time t given the previous observation, and therefore
assumes dependence between these observations,
would be a valid model to test because data were
collected frequently and longitudinally over time. The
PPC analysis of the number of different categorical
transitions for both lorazepam sleepiness and dizzi-
ness simulated form the logistic models, show that the
observed population mean lies within the posterior
distributions for the number of the different transi-
tions. The posterior distributions capture the
observed mean adequately overall with the exception
of few transitions which lie at the tail of the posterior
distribution as shown in Figure 6a (lorazepam sleepi-
ness) and 6b (lorazepam dizziness). Although the
Markov model may be better suited for simulating
individual profiles, the current logistic model appears
to predict the general trend of lorazepam sleepiness
and dizziness reasonably well as shown in Figure 4.
Finally, certain study caveats should be acknowl-
edged. First, the current study differentiates two
AEs of a single drug. It would also be of interest to
differentiate the same AE between two drugs in a
similar therapeutic class; however, the drugs
included in the larger study4 were of different
therapeutic classifications. Second, the low incidence
of other AEs observed in this study precluded
application of this modeling approach to other AEs
(of lower intensity).4 Nevertheless, the model pro-
posed, may serve as platform to determine the
minimal quantifiable categorical signal, given a
particular study design and power, by conducting a
sensitivity analysis31 on model parameters. Third,
only a single therapeutic dose was investigated. Use
of higher doses would better elucidate the maximal
categorical response for such AEs. This information
would have allowed determination of maximal
capacity (Emax) of the system and sensitivity (EC50)
of AEs, enhancing the interpretability of the current
analysis. Such an analysis may be feasible in
ascending dose studies of compounds under develop-
ment. Fourth, the study was conducted on healthy
volunteers as opposed to patients with anxiety.
Extrapolation of adverse event endpoints from healthy
volunteers to patients may not be straightforward, as
the tolerance of these different populations to AEsDOI 10.1002/jps
PHARMACODYNAMIC DIFFERENTIATION OF LORAZEPAM SLEEPINESS AND DIZZINESS 3641may be quite different. This has been seen in certain
CNS indications such as schizophrenia where
patients have shown higher tolerance to AEs of
antipsychotic medications.32 Despite the limitations
of the study, we believe the current analysis has
demonstrated the feasibility of differentiating certain
AEs using the pharmacometric approach described
and may provide a framework for future studies with
a similar aim.
CONCLUSION
Lorazepam sleepiness and dizziness have shown
distinct temporal PK/PD patterns and were recorded
with significantly different intensity on the seven-
point categorical scale. Differences in the PD end-
points described may be due to differences in baseline
parameters. The differences between data-derived
PD measures of sleepiness and dizziness were con-
sistent with differences in incidence rates reported in
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